NSCLC METex 14 Skipping

In this OncoTalks episode, Dr. David Waterhouse and Dr. Paul Conkling discuss NSCLC and the groundbreaking developments in treating patients with METex 14 skipping mutations. We review the science behind these targeted therapies, their clinical applications, and the impact on patient outcomes. This episode offers vital information to help navigate treatment options and empower patients. Don’t miss this engaging discussion on a crucial topic in oncology, filled with expert insights!